Area of research
Pathology and Forensic Medicine · Otorhinolaryngology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Head and Neck Cancer Studies, Viral-associated cancers and disorders, and Lung Cancer Treatments and Mutations.
Epigenetically conferred ring-stage survival in Plasmodium falciparum against artemisinin treatment
Visible-Light-Induced α-Arylation of Ketones with (Hetero)aryl Halides
Up-Regulated MiR-616-5p Promotes the Progression of Nasopharynx Cancer through GSK3<i>β</i>
[Neoadjuvant treatment by toripalimab combined with chemotherapy for advanced poorly differentiated tonsillar squamous cell carcinoma: a case report].
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Donafenib in Locally Advanced/Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (DIRECTION)
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial
5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients
Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study
JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Improved Overall Survival Associated With Decreased Distant Metastasis Following Asparaginase-Based Chemotherapy and Radiotherapy for Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in <i>KRAS</i> wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial
Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
P2.13-30 High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer with EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study
OA13 High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study
A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type <i>K-ras</i> metastatic colorectal cancer patients.
Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer
Primary Breast Diffuse Large B Cell Lymphoma in the Rituximab Era: Outcomes of a Multicenter Retrospective Study By the Lymphoma and Leukemia Committee of Chinese Geriatric Oncology Society(LLC-CGOS)
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma
Increased expression of Mitotic Arrest Deficient-Like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer